BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer
Open Access
- 15 June 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (12)
Abstract
Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cancer cell lines, freshly resected human bladder tumors, and samples from cohorts of patients with bladder cancer before and after BCG therapy, we demonstrate 2 distinct patterns of immune subversion upon BCG relapse. In the first pattern, intracellular BCG infection of cancer cells induced a posttranscriptional downregulation of HLA-I membrane expression via inhibition of autophagy flux. Patients with HLA-I–deficient cancer cells following BCG therapy had a myeloid immunosuppressive tumor microenvironment (TME) with epithelial-mesenchymal transition (EMT) characteristics and dismal outcomes. Conversely, patients with HLA-I–proficient cancer cells after BCG therapy presented with CD8+ T cell tumor infiltrates, upregulation of inflammatory cytokines, and immune checkpoint–inhibitory molecules. The latter patients had a very favorable outcome. We surmise that HLA-I expression in bladder cancers at relapse following BCG does not result from immunoediting but rather from an immune subversion process directly induced by BCG on cancer cells, which predicts a dismal prognosis. HLA-I scoring of cancer cells by IHC staining can be easily implemented by pathologists in routine practice to stratify future treatment strategies for patients with urothelial cancer.Keywords
Funding Information
- Institut Gustave-Roussy (MSD Avenir, SIRIC SOCRATE)
- IdEx Université de Paris (IdEx Université de Paris ANR-18-IDEX-0001)
- Columbia University (NIH/NCI U01CA247573)
- Institut Imagine (ANR-10-IAHU-01)
This publication has 36 references indexed in Scilit:
- Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer CellsCancer Research, 2013
- Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating CellsCancer Cell, 2012
- Trial WatchOncoImmunology, 2012
- Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder CancerScience Translational Medicine, 2012
- Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic ReviewEuropean Urology, 2011
- Bacillus Calmette‐Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I‐deficient tumor cellsInternational Journal of Cancer, 2010
- Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptorsNature Reviews Microbiology, 2010
- CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell ImmunityJournal of Immunotherapy, 2008
- Genome plasticity of BCG and impact on vaccine efficacyProceedings of the National Academy of Sciences, 2007
- A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the BladderNew England Journal of Medicine, 1991